Acadia Pharmaceuticals Inc
ACAD
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.05B
Close$
$-11.14
136.9% downside
Current Fair Value
136.9% downsideOvervalued by 136.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.05 Billion |
|---|---|
| Enterprise Value | $4.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.32 |
| Beta | 0.85 |
| Outstanding Shares | 171,603,000 |
Return
| Return on Equity | 29.12% |
|---|---|
| Return on Assets | 21.83% |
| Return on Invested Capital | 6.27% |
Valuation & Multiples
| P/E Ratio | 13.11 |
|---|---|
| PEG | 72.33 |
| Price to Sales | 5.03 |
| Price to Book Ratio | 4.31 |
| Enterprise Value to Revenue | 4.16 |
| Enterprise Value to EBIT | 54.7 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$295.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.20
Average shareholder expectationRevenue Estimate
$331.60 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0008▲ 31.99% |
|---|---|
| Total Calls | 246,100▼ 54.60% |
| Total Puts | 246,300▼ 33.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.78%▲ 0.49% |
|---|---|
| Total Invested | $4.24B▲ 15.52% |
| Investors Holding | 356▼ 1.00% |
ESG Score
No data
About Acadia Pharmaceuticals Inc
CEO: Uli Hacksell